Gamco Investors INC. ET AL Acquires 20,257 Shares of Henry Schein, Inc. $HSIC

Gamco Investors INC. ET AL increased its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 5.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 382,452 shares of the company’s stock after buying an additional 20,257 shares during the period. Gamco Investors INC. ET AL’s holdings in Henry Schein were worth $25,383,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its stake in shares of Henry Schein by 47.3% in the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock worth $2,071,000 after acquiring an additional 9,756 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Henry Schein by 1.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock valued at $1,155,000 after purchasing an additional 229 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Henry Schein in the first quarter valued at approximately $676,000. Envestnet Asset Management Inc. raised its position in Henry Schein by 103.1% in the 2nd quarter. Envestnet Asset Management Inc. now owns 91,299 shares of the company’s stock worth $6,669,000 after purchasing an additional 46,357 shares during the last quarter. Finally, Atria Investments Inc bought a new position in Henry Schein in the 2nd quarter worth approximately $458,000. Institutional investors own 96.62% of the company’s stock.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, CEO Stanley M. Bergman sold 43,812 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $81.31, for a total value of $3,562,353.72. Following the transaction, the chief executive officer owned 383,803 shares of the company’s stock, valued at approximately $31,207,021.93. This represents a 10.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Philip A. Laskawy sold 2,844 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $80.36, for a total value of $228,543.84. Following the transaction, the director owned 21,961 shares in the company, valued at approximately $1,764,785.96. This trade represents a 11.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 101,712 shares of company stock valued at $8,251,789. 1.08% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Wells Fargo & Company increased their price objective on Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. Leerink Partners upped their price target on Henry Schein from $75.00 to $87.00 and gave the company a “market perform” rating in a research note on Tuesday, February 24th. Wall Street Zen upgraded Henry Schein from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Robert W. Baird set a $100.00 price objective on Henry Schein and gave the stock an “outperform” rating in a research report on Monday, February 23rd. Finally, UBS Group boosted their price objective on Henry Schein from $79.00 to $87.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $85.58.

Henry Schein Price Performance

HSIC opened at $77.60 on Friday. The company has a fifty day moving average price of $78.20 and a two-hundred day moving average price of $72.57. The firm has a market capitalization of $8.90 billion, a PE ratio of 23.73, a P/E/G ratio of 2.37 and a beta of 0.88. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $89.29. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.38.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The company had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.34 billion. During the same quarter in the prior year, the business posted $1.19 EPS. The firm’s quarterly revenue was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.